

INFORMATION ONLY

Renewal Request Process for Glassia Customer Letter # 2025-14

2025-05-01

Dear Colleagues:

Background:

Canadian Blood Services began listing Glassia (alpha-1 proteinase inhibitor [A1-PI]), manufactured by Takeda on Feb 29, 2024. Access to Glassia has been managed through Canadian Blood Services' Special Authorization program (previously Named Patient Contract process). All Glassia requests are approved for a maximum duration of one year.

For renewal of the authorization, a new *Request for Designated Plasma Protein and Related Products* form must be submitted to Canadian Blood Services prior to the expiry of the current authorization or in advance of depleting the approved quantities. Forms are requested to be submitted at minimum of 2 weeks prior to requiring the product. Please note that review and approval times may take longer if the request is submitted under exceptional access (i.e, for use outside the listed criteria).

The renewal process is as follows:

- For Section 1 of the form, please include all previously provided information on the hospital, contacts and patient. Please update as required.
- For Section 2, select the "Renewal" box and contract number if available.
- For Section 3,
 - Add requested Glassia dose specified under 'New Therapy' or by checking the 'Current Therapy' box.
 - Confirm that the patient still meets the criteria, by providing the following information and confirmations:
 - Recent or updated FEV1 value within the last year
 - Nonsmoker for at least 6 months
 - Has not received a lung transplant
- The updated form must be submitted to Canadian Blood Services at <u>SAPPRPRequests@blood.ca</u> or to their local Canadian Blood Services distribution site to request access for their patients.



 The request will be reviewed and approved by Canadian Blood Services' Special Authorization team, after which a contract renewal confirmation will be sent to the clinic contact listed on the request.

Requesting and Ordering Glassia

Glassia can be ordered from Canadian Blood Services using the patient's contract number through either the Online Ordering Portal or by completing the <u>Order Form for Plasma Protein</u> and Related Products Requiring Contracts.

Any questions regarding the patient support program (PSP) or administration of Glassia should be directed to the OnePath program:

Email: <u>support@onepathprogram.ca</u>

• Tel: 1-844-691-7284

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the "Hospital Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Dr. S. Grenier Director, Plasma Protein and Related Products Formulary Program